Gaucher disease: 2026 so far

Long follow-up and registry data sharpened real-world ERT expectations.

In the months covered, large real-world follow-up reports described improvements linked with ERT in blood counts, organ size, and bone pain. These changes were reported to show up within 1 to 5 years and to be sustained through 10 to 15 years. Starting ERT earlier was linked with larger early gains in blood counts. Registry comparisons also suggested that some clinically stable type 1 patients had similar tracked outcomes when infusions were spaced to every 3 to 4 weeks instead of every 2 weeks. This frames infusion frequency as an active real-world question, not a settled standard. Other cohorts added detail in specific settings, such as 1-year velaglucerase alfa outcomes in China and a single low-resource case describing multi-year improvement on imiglucerase. In practical terms, these reports describe what has been seen in routine care about how durable ERT benefits can be and where dosing flexibility is being explored, while still being observational rather than definitive proof for any one person.

Research covered in: February 2026, June 2026, July 2026

Multiple small real-world reports linked eliglustat to marker drops.

In several real-world reports from the months covered, eliglustat in type 1 Gaucher disease was linked with decreases in Gaucher blood markers lyso-Gb1/lyso-GL1 (blood markers that reflect Gaucher-related lipid buildup). These reports also described increases in platelet counts and decreases in liver and spleen volumes over months to a year. Safety summaries described suspected drug-related side effects in 27.8% in one dataset. These were mostly mild stomach or skin issues, and that dataset reported no serious events or treatment stops. In the small 5-person report, one participant reported mild nausea and reduced appetite that resolved within 2 days; no other adverse events were reported in the summary. One long-followed cohort also reported that eliglustat suppressed LysoGL1 more deeply than ERT, in the context of an observational analysis of MGUS risk. For day-to-day care, these reports suggest eliglustat is being followed using the same kinds of blood markers and organ measurements used in Gaucher care, while the evidence in these reports is observational and often based on small numbers.

Research covered in: March 2026, May 2026, June 2026

Patient-reported burden was quantified alongside clinical measures.

In June, a study in treated adults with type 1 Gaucher disease found that higher pain interference (how much pain disrupts daily activities) and higher fatigue each strongly predicted worse physical and mental quality-of-life scores. Participants reported lower quality of life than population norms across most areas measured. Separately, multi-year follow-up work described gradual increases in subtle movement signs and some non-motor symptoms. Among participants tested, hearing loss was common and often worsened over time. This highlighted that day-to-day burden can change over time even with ongoing Gaucher care. These reports did not identify which interventions best reduce pain or fatigue. They did clarify how closely these symptoms track with how people feel and function, meaning symptom tracking (not only labs and organ size) remained a major part of understanding lived experience in treated Gaucher cohorts.

Research covered in: April 2026, June 2026

More sensitive tests highlighted risks not captured by counts alone.

In the months covered, several studies suggested that standard measures may not capture everything. In one small study, treated adults with type 1 Gaucher disease had higher liver and spleen stiffness than matched controls even though their organs were smaller. In that study, liver stiffness tracked with liver enzymes, ferritin, and longer disease duration. Later, repeated-measures work found liver stiffness predicted higher overall disease severity scores over time. A separate long-followed cohort reported MGUS (monoclonal gammopathy of undetermined significance, an abnormal blood protein finding) occurring more often than expected. In that cohort, longer Gaucher-therapy exposure was linked to fewer new MGUS diagnoses, but this was observational and not randomized. In September, a large follow-up platelet-function study found a platelet secretion abnormality (CD62P-related) often persisted over time. It could occur even when platelet counts were in a typical range. The study did not connect these lab patterns to bleeding outcomes. Taken together, these findings point to situations where imaging-based liver measures, longer-term blood-protein monitoring questions, and platelet function testing may show Gaucher-related burden that does not line up neatly with routine counts alone.

Research covered in: January 2026, May 2026, June 2026, September 2026

Surveys and screening programs quantified delays and mislabeling.

In the months covered, multiple reports pointed to ongoing gaps in diagnosis. A patient/caregiver survey reported that more than half waited over a year for diagnosis. Dried blood spot programs (testing from a finger-prick blood sample on filter paper) showed both feasibility and real-world barriers, including sample quality, heat/humidity effects, and incomplete genetic confirmation. In August, a very large multiplex dried-blood screening effort showed that among people referred for suspected Gaucher disease, some were ultimately confirmed to have acid sphingomyelinase deficiency (ASMD) instead. Overall, the program confirmed equal numbers of Gaucher disease and ASMD diagnoses. This highlights that similar symptoms can lead to the same referral pathway but require different disease labels and treatments. Case reports also showed that in low-resource settings, Gaucher diagnosis may remain presumptive (based on strong suspicion, without full confirmation) when confirmatory enzyme/genetic testing is unavailable. In real life, these reports underline how access to reliable confirmatory testing and broader lysosomal-disease screening pathways can affect whether families receive a definitive diagnosis and how long that can take.

Research covered in: February 2026, July 2026, August 2026, September 2026